Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Oryzon Genomics SA ( (ES:ORY) ) is now available.
Oryzon Genomics has submitted the protocol for its Phase III PORTICO-2 clinical trial to the FDA, aiming to evaluate the efficacy of vafidemstat in treating Borderline Personality Disorder (BPD). This trial is significant as it seeks to address the unmet medical need of reducing aggression in BPD patients, building on promising results from previous studies and marking a major advancement for both the company and the neuropsychiatry field.
The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.
More about Oryzon Genomics SA
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in epigenetics. The company focuses on developing innovative therapies, particularly in the field of neuropsychiatry, with a market focus on addressing unmet medical needs in personality disorders.
YTD Price Performance: 94.29%
Average Trading Volume: 729,342
Technical Sentiment Signal: Buy
Current Market Cap: €210.8M
Find detailed analytics on ORY stock on TipRanks’ Stock Analysis page.